Biosensors International Group, Ltd
Kenneth Graham has over 20 years of experience in the healthcare industry, specifically in sales and leadership roles. Kenneth began their career at Eli Lilly in 2000 as a Sales Director for Northern Europe, where they managed a specialist sales team and led the EU KOL management team. In 2008, they joined Biosensors International as Vice President Sales EMEA & Managing Director of Biosensors Europe SA, where they oversaw sales operations and strategic management for the region.
Kenneth Graham completed their education from 1983 to 1987 at the University of Stirling. During this time, they pursued a Bachelor of Science degree in Biochemistry.
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.